Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.

Latest From Cathy Kelly

Gilead Assistance Programs For HIV, Hep B Drugs Will Dial Back Reimbursement To 340B Providers

HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.

Pricing Strategies Infectious Diseases

Higher Medicaid Rebates For Expedited Approvals Offer Modest Savings But Target Growing Concern

As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.

Pricing Debate Medicaid

Roxadustat Approval Might Hinge On Additional Safety Analyses After FibroGen Admits Manipulating Data

With superiority over epoetin apparently off the table, FibroGen and AstraZeneca expect a US FDA advisory committee in July, and hope that additional safety analyses for roxadustat will help support a positive overall risk-benefit profile.

Clinical Trials Regulation

Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx

A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.

Market Access Pricing Strategies

US-Funded Research On Remdesivir Did Not Produce ‘Patentable’ Discoveries

US government agencies were given the right to pursue patents on remdesivir in research contracts negotiated with Gilead but did not do so, the Government Accountability Office reports. 

Pricing Debate Intellectual Property

Aurinia’s Dosing Patent For Lupkynis A ‘Slippery Slope’ To Extending US Market Exclusivity?

The Institute for Clinical and Economic Review raises concerns about the cost implications of companies obtaining extended market exclusivity by patenting the treatment protocol used for drugs in clinical trials.

Intellectual Property Life Cycle Management
See All
UsernamePublicRestriction

Register